LXH254,LXH-254

Request For Quotation
LXH254,LXH-254 Suppliers list
Company Name: Suzhou Chenrui Biotechnology Co. LTD  Gold
Tel: 17625585511
Email: 1580084073@qq.com
Company Name: WUHAN SUN-SHINE BIO-TECHNOLOGY Co., Ltd.  
Tel: 17702719238
Email: sales@sun-shinechem.com
Company Name: AdooQ Bioscience CHINA  
Tel: 025-58849295
Email: info@adooq.cn
Company Name: Shanghai Lollane Biological Technology Co.,Ltd.  
Tel: 021-52996696，15000506266 15000506266
Email:
Company Name: Shanghai EFE Biological Technology Co., Ltd.  
Tel: 021-65675885 18964387627
Email: info@efebio.com

LXH254,LXH-254 manufacturers

  • LXH254
  • LXH254 pictures
  • $124.00
  • 2026-08-30
  • CAS:1800398-38-2
  • Purity: 99.31%
  • Supply Ability: 10g
  • LXH254
  • LXH254 pictures
  • $124.00
  • 2026-07-27
  • CAS:1800398-38-2
  • Purity: 99.31%
  • Supply Ability: 10g
LXH254,LXH-254 Basic information
Product Name:LXH254,LXH-254
Synonyms:LXH254; LXH-254; LXH 254;LXH254,LXH-254;LXH254;4-Pyridinecarboxamide, N-[3-[2-(2-hydroxyethoxy)-6-(4-morpholinyl)-4-pyridinyl]-4-methylphenyl]-2-(trifluoromethyl)-;Bcr-Abl,A375,Inhibitor,p38 MAPK,LXH 254,inhibit,Raf,Mia PaCa-2,Raf kinases,HCT116,LXH254,Selective,MEL-JUSO,LXH-254;N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide;Naporafenib (LXH-254);N-[3-[2-(2-Hydroxyethoxy)-6-morpholino-4-pyridyl]-4-methylphenyl]-2-(trifluoromethyl)isonicotinamide
CAS:1800398-38-2
MF:C25H25F3N4O4
MW:502.49
EINECS:
Product Categories:
Mol File:1800398-38-2.mol
LXH254,LXH-254 Structure
LXH254,LXH-254 Chemical Properties
Boiling point 601.9±55.0 °C(Predicted)
density 1.353±0.06 g/cm3(Predicted)
storage temp. Store at -20°C
solubility DMSO:100.0(Max Conc. mg/mL);199.0(Max Conc. mM)
form A crystalline solid
pka10.86±0.70(Predicted)
color Off-white to light yellow
InChIKeyUEPXBTCUIIGYCY-UHFFFAOYSA-N
SMILESC1(C(F)(F)F)=NC=CC(C(NC2=CC=C(C)C(C3C=C(N4CCOCC4)N=C(OCCO)C=3)=C2)=O)=C1
Safety Information
HS Code 2934999090
MSDS Information
LXH254,LXH-254 Usage And Synthesis
UsesLXH254, is a kinase inhibitor used in the treatment of solid tumors.
in vivo

Treatment with Naporafenib (Compound A) generates tumor regression in several KRAS-mutant models including the NSCLC-derived Calu-6 (KRAS Q61K) and NCI-H358 (KRAS G12C). Naporafenib exhibits efficacy in numerous MAPK-driven human cancer cell lines and in xenograft tumors representing model tumors harboring human lesions in KRAS, NRAS and BRAF oncogenes[1].
Naporafenib shows significant antitumor activity in models harboring BRAF mutations either alone or coincident with either activated NRAS or KRAS, and RAS mutants lacking ARAF are more sensitive to Naporafenib[2].

Animal Model:Outbred athymic (nu/nu) female mice and SCID Beige mice; BRAF-, NRAS-, and KRAS-mutant xenograft models, as well as a RAS/RAF wild-type model[2]
Dosage:100 mg/kg
Administration:Orally, daily
Result:Significantly decreased tumor volume in models harboring BRAF mutations either alone or coincident with either activated NRAS or KRAS, slightly decreased tumor volume in KRAS model.
IC 50CRAF: 0.072 nM (IC50); Braf: 0.21 nM (IC50); ARAF: 6.4 nM (IC50); p38α: 2.1 μM (IC50); Abl1: 4.9 μM (IC50)
LXH254,LXH-254 Preparation Products And Raw materials
Tag:LXH254,LXH-254(1800398-38-2) Related Product Information
LXH254,LXH-254 BI 882370 RAF709 ZM 336372 Belvarafenib RO5126766(CH5126766)